• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Protalix Biotherapeutics (NY: PLX )

    1.185 -0.035 (-2.87%)
    Streaming Delayed Price Updated: 11:09 AM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Protalix Biotherapeutics

    < Previous 1 2 3 Next >
    PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Beats Revenue for Q2 2024
    PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024
    PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Pullix Gains Momentum As Gamestop Exits NFT Space
    Notable NFT news this week is from video game retailer GameStop, which has announced its NFT marketplace will shut down next month. The publicly-traded company is citing “regulatory uncertainty” for... 
    Via Talk Markets
    Earnings Scheduled For November 6, 2023
    Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
    Via Benzinga
    Earnings Preview For Protalix BioTherapeutics
    Via Benzinga
    Preview: Protalix BioTherapeutics's Earnings
    Via Benzinga
    Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil
    Via Benzinga
    Earnings Scheduled For March 14, 2024
    Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
    Via Benzinga
    Earnings Preview: Protalix BioTherapeutics
    Via Benzinga
    Earnings Preview For Protalix BioTherapeutics
    Via Benzinga
    Looking Into Protalix BioTherapeutics's Return On Capital Employed
    Via Benzinga
    Protalix BioTherapeutics Well Placed to Advance in 2023
    We see a number of reasons to be positive about PLX shares in 2023 and investors should take note. 
    Via Talk Markets
    Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying
    The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
    The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult  
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    It's time for another dive into the biggest pre-market stock movers as we see what shares are on rising and falling on Tuesday! 
    Via InvestorPlace
    Earnings Scheduled For May 16, 2022
    Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
    Via Benzinga
    Protalix PRX-102: Likely Approval Could Be A Game Changer
    Protalix's PRX-102 drug stands a good chance of being accepted against Fabry disease, with three P3 trials delivering good results. 
    Via Talk Markets
    Why Lucira Health Shares Are Trading Higher By Over 228%; Here Are 20 Stocks Moving Premarket
    Gainers Lucira Health, Inc. (NASDAQ: LHDX) rose 228.5% to $0.46 in pre-market trading after the FDA authorized Lucira's over-the-counter at-home test to detect both influenza and COVID-19 viruses. 
    Via Benzinga
    $12.5 Million Bet On Biodesix? Check Out These 4 Penny Stocks Insiders Are Buying
    The Dow Jones closed lower by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
    Via Benzinga
    Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
    By David Willey, Benzinga 
    Via News Direct
    Exposures Product Safety
    Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
    Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, 
    Via Benzinga
    Earnings Scheduled For February 27, 2023
    Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
    Via Benzinga
    Earnings Scheduled For November 14, 2022
    Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million. 
    Via Benzinga
    Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
    By Mark Gilman, Benzinga 
    Via News Direct
    Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
    As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a... 
    Via Benzinga
    10 Most-Searched Tickers On Benzinga Pro In April: Musk Mania, Apple Drops, Several Newcomers Move Up
    Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Here is a look at the... 
    Via Benzinga
    Earnings Scheduled For August 15, 2022
    Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter. 
    Via Benzinga
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.